A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines

Allergan logo

Allergan

Status

Completed

Conditions

Chronic Migraine, Headaches

Treatments

Biological: onabotulinumtoxinA

Study type

Observational

Funder types

Industry

Identifiers

NCT01749410
GMA-BTX-CM-12-491

Details and patient eligibility

About

This study will evaluate the effectiveness and benefit of treatment with onabotulinumtoxinA in Chronic Migraine patients who have received a minimum of 7 treatment cycles.

Enrollment

33 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 15 or more headache days over a 30 day period
  • A minimum of 7 treatment cycles with onabotulinumtoxinA

Exclusion criteria

  • Any treatment cycle dose of onabotulinumtoxinA greater than 200 units

Trial design

33 participants in 1 patient group

All participants
Description:
Previous treatment with onabotulinumtoxinA for Chronic Migraine based on retrospective medical record review.
Treatment:
Biological: onabotulinumtoxinA

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems